Heart Failure 2022: Implementing Meaningful Change

Overview
This program discusses new approaches for clinicians that have not been part of their armamentarium for the management of heart failure with reduced ejection fraction (HFrEF). Several new therapeutic options targeting different mechanisms enable providers to incorporate the latest clinical data into their clinical practice. Clinical practice patterns for both the cardiovascular specialist and the general provider will need to evolve to improve the standard of care when managing patients with HFrEF.
Target Audience
This activity has been designed to meet the educational needs of the multi-disciplinary team, including physicians, nurses and pharmacists involved in the care of patients with heart failure with reduced ejection fraction (HFrEF).
Learning Objectives
After participating in this educational activity, participants should be better able to:
1. Discuss the clinical application of the latest guidelines and describe the implementation of strategies to improve adherence and clinical outcomes in patients with HFrEF
2. Discuss treatment strategies for the management of HFrEF patients across cardiovascular and non-cardiovascular specialties
3. Discuss newer pharmacologic interventions and integrate them within the current practice for appropriate patients
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Global Learning Collaborative (GLC) designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Learning Collaborative (GLC) designates this activity for 1.0 hour(s) of Nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.10 CEUs of Pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-22-019-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
The following faculty have reported relationships with ineligible companies:

Stephen J. Greene, MD, planner and faculty for this educational event, receives consulting fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Merck, PharmaIN, Roche Diagnostics, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor; and receives research funds from AstraZeneca, Amgen, Cytokinetics, Pfizer, Merck, Novartis, and Sanofi.

Cody Carson, PharmD, BCPS, faculty for this educational event, has no relevant financial relationships with ineligible companies.

Jaime McDermott, DNP, RN, ACNP-BC, CV-BC, CCRN, CHFN, faculty for this educational event, has no relevant financial relationships with ineligible companies.

Javed Butler, MD, MPH, MBA, faculty for this educational event, received consulting fees from Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharma, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sequana Medical, and Vifor.

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP, faculty for this educational event, receives consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb, scPharmaceuticals, Baxter Healthcare Corporation, Sanofi-Aventis, Relypsa, and Vifor; and receives research funds from Liva Nova, Cardurion and Abbott.

All the relevant financial relationships for these individuals have been mitigated.
Planners and Managers Disclosure List
The following reviewers/planners have reported no relationships with ineligible companies:

Vin Kalathiveetil, PharmD, planner for this educational event, has no relevant financial relationships with ineligible companies.

Prerna Poojary, PhD, planner for this educational event, has no relevant financial relationships with ineligible companies.

William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

All the relevant financial relationships for these individuals have been mitigated.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TotalCME, Inc., the CME providers, or the companies providing educational grants. This presentation is not intended to define an exclusive course of patient management; the participant should use their clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.

Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Acknowledgment
This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.
Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.
Fee Statement
This activity is FREE to all participants.
Instructions for Completion
During the period 6/30/2022 through 6/30/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:
1. Read the learning objectives and faculty disclosures.
2. Answer a pre-program question.
3. View the program.
4. Complete the post-test with a score of 100%.
5. Complete activity evaluation.
6. Apply for credit and either bank your credits or print your certificate.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Publication Dates
Release Date: 06/30/2022
Expiration Date: 06/30/2023